ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), is a rapidly growing pharmaceutical company, with the third largest branded prescription eye care business* in the United States and an emerging allergy drug franchise. The Company’s marketed products and development pipeline candidates are intended to address key segments of the $6.5 billion ophthalmic pharmaceutical market and the $2.5 billion nasal allergy market.
ISTA currently markets four prescription products in the United States: BROMDAY™ (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery; BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%, recently launched for the treatment of ocular itching associated with signs and symptoms of allergic conjunctivitis;  ISTALOL ® (timolol maleate ophthalmic solution) 0.5% for the treatment of glaucoma; and VITRASE ® (hyaluronidase injection) Ovine, 200USP Units/mL for use as a spreading agent.  BROMDAY, ISTALOL and VITRASE are each market leaders in their respective categories, with BROMDAY and ISTALOL continuing to grow faster than their market segments.  To fuel the Company’s long-term growth, ISTA has several eye and allergy product candidates in various stages of development, including treatments for dry eye, ocular inflammation and pain and nasal allergies. 

Headquartered in Irvine, California, ISTA Pharmaceuticals had 2010 revenues of $157 million. The Company has a staff of 326 employees, 167 of which are part of a scaled-up sales force calling on ophthalmologists, optometrists and allergists across the U.S.  For additional information about ISTA Pharmaceuticals, please visit www.istavision.com.

* IMS HEALTH data measuring sales prescribed by ophthalmologists

Our Products

• Our Product Pipeline

Company Timeline